The Law Offices of Frank R. Cruz and Kaplan Fox & Kilsheimer LLP both announced on August 12, 2026, that they are continuing or initiating investigations into potential securities law violations by Hims & Hers Health Inc. (NYSE: HIMS). Adding to this coalition, Kessler Topaz Meltzer & Check, LLP also announced on August 12, 2026, that it is investigating potential violations of federal securities laws by Hims & Hers on behalf of investors who purchased or acquired securities and experienced significant financial losses. This development expands the scrutiny on the telehealth provider following a July 29, 2026, lawsuit filed by the U.S. Federal Trade Commission (FTC), alongside the States of Utah and California.

The FTC’s enforcement action, filed in the U.S. District Court for the Northern District of California, alleges that Hims & Hers engaged in unlawful business practices. Key accusations include charging consumers for prescriptions before medical consultations occurred, enrolling them in recurring subscriptions without approval, and making it difficult to cancel subscriptions. Crucially, the complaint asserts the company shared sensitive health information with third-party advertising platforms, specifically Meta Platforms Inc. and Snap Inc., despite representing that such data would remain private. The filing cites violations of the FTC Act, the Restore Online Shoppers’ Confidence Act, the Utah Consumer Sales Practices Act, and California’s False Advertising and Unfair Competition Laws.

Market Reaction and Technical Outlook

The market reacted sharply to the regulatory news, with Hims & Hers shares falling over 14% on July 29, 2026, closing at $25.00 after a $4.32 drop. Lowey Dannenberg noted an intraday decline of $3.05 per share, or approximately 10.40%, during trading on July 29, 2026. Despite the initial sell-off, the stock recovered ground in subsequent trading, rising 2.44% to close at $27.70 on Friday. This rebound placed the stock just 0.7% above its 100-day simple moving average (SMA) of $27.51. However, technical indicators remain cautious; the share price remains 14.9% below its 20-day SMA ($32.54) and 9.8% below its 50-day SMA ($30.72). The MACD indicator remains below its signal line with a negative histogram, suggesting that upside pressure may cool unless buyers can reclaim the $30.00 resistance level.

Financial Context and Company Response

The legal challenges emerge amid mixed financial performance for the telehealth provider. In the first quarter, Hims & Hers posted a loss of 40 cents per share, missing analyst estimates of 4 cents per share. Revenue totaled $608.1 million, falling below the Street consensus estimate of $616.9 million. However, the company maintains a robust outlook for the second quarter, with expected revenue between $680 million and $700 million, surpassing analyst estimates of $642.95 million. Adjusted EBITDA is projected between $35 million and $55 million.

Hims & Hers Health vehemently denied the allegations, asserting that the government’s case ignores substantial evidence provided during a nearly three-year investigation. A company representative stated that the lawsuit "disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and industry standards in telehealth, and contorts the law to try to manufacture claims." The company characterized the enforcement action as an effort to generate headlines rather than grounded consumer protection.

What the Numbers Show

The divergence between Hims & Hers’ strong Q2 revenue guidance ($680–$700 million) and the immediate volatility highlights a market reassessment of risk. While operational metrics remain resilient, the introduction of federal litigation regarding core business practices—data monetization and billing transparency—suggests investors are pricing in significant potential liabilities beyond standard quarterly performance variances. The addition of Kaplan Fox & Kilsheimer LLP, Kessler Topaz Meltzer & Check, LLP, Lowey Dannenberg P.C., Kirby McInerney LLP, Schall, Brown & Schwartz LLP, The Law Offices of Frank R. Cruz, Holzer & Holzer, LLC, and Bragar Eagel & Squire, P.C., to the list of investigating firms signals growing confidence among plaintiffs' attorneys that the FTC's findings may support viable securities fraud claims, even as technical indicators suggest the stock is attempting to base near its 100-day SMA.

Lowey Dannenberg, P.C. filed the first class action complaint against Hims & Hers Health, Inc. on Aug. 11, 2026, alleging the company misrepresented its platform’s privacy protections and secretly shared consumers’ sensitive health information with third-party advertisers without consent. The consumer lawsuit arrives one day after the Federal Trade Commission (FTC), joined by the People of the State of California and the Utah Division of Consumer Protection, initiated a civil enforcement action against the telehealth provider. On Aug. 12, 2026, national plaintiffs’ law firm Berger Montague PC announced an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) for potential breaches of fiduciary duties owed to the company and its shareholders.

These coordinated legal challenges expose significant regulatory and reputational risks for Hims & Hers. Authorities allege systematic violations of federal and state privacy laws alongside deceptive billing practices that enrolled users in recurring subscriptions without genuine medical consultations. The Berger Montague investigation focuses on whether the company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made subscription cancellations unnecessarily difficult.

The FTC’s investigation, which began with a Civil Investigative Demand in October 2023, culminated in a complaint filed on July 29, 2026, in the U.S. District Court for the Northern District of California (Case No. 3:26-cv-07871). The regulatory action accuses Hims & Hers of violating multiple statutes, including Section 5(a) of the FTC Act (15 U.S.C. § 45(a)) and Section 4 of the Restore Online Shoppers’ Confidence Act (ROSCA) (15 U.S.C. § 8403). Additionally, the complaint cites breaches of California’s Unfair Competition Law (Cal. Bus. & Prof. Code § 17200 et seq.) and False Advertising Law (Cal. Bus. & Prof. Code § 17500 et seq.), as well as the Utah Consumer Sales Practices Act (Utah Code § 13-11-4(1)).

Deceptive Billing Allegations

According to the FTC complaint, Hims & Hers advertised "free consultations" and informed consumers completing online medical intake forms that they would "only be charged if prescribed." In practice, however, the company routinely charged users and enrolled them in recurring prescription subscriptions almost immediately after a provider reviewed their intake form, often without offering a genuine consultation. The complaint further alleges that Hims & Hers made it difficult for consumers to cancel these subscriptions, trapping users in billing cycles they did not explicitly authorize.

Privacy Violations and Data Sharing

The core of both the regulatory and class action complaints centers on the alleged misuse of sensitive health data. While Hims & Hers assured consumers that their health information was private and visible only to medical providers, the FTC alleges the company instead opted to grow revenue streams by sharing this data with advertising platforms such as Meta Platforms, Inc., Google LLC, and Snap Inc. Lowey Dannenberg’s class action specifically claims these disclosures occurred without adequate disclosure or consent, violating the California Invasion of Privacy Act, Common Law Invasion of Privacy - Intrusion Upon Seclusion, the California Confidentiality of Medical Information Act, and the Electronic Communications Privacy Act.

What the Numbers Show

The convergence of federal enforcement, private litigation, and a board-level fiduciary duty investigation highlights a critical divergence between Hims & Hers’ public privacy assurances and its operational data-sharing practices. By leveraging sensitive health data for advertising revenue via pixels and software development kits, the company prioritized growth over compliance, directly contradicting regulator guidance that such practices are inappropriate. This pattern suggests systemic governance failures in how user consent is managed and monetized, posing substantial liability risks beyond immediate fines.

Christian Levis, Partner and Chair of the Data Privacy Practice at Lowey Dannenberg, stated that the complaint reflects the firm’s commitment to protecting individuals’ private health data. Amanda Fiorilla, Partner and Vice Chair of the Data Privacy Practice at Lowey, added that sharing private health data through pixels and software development kits is unacceptable given clear government regulator guidance. Affected consumers may check eligibility for the class action via Claim Magic at https://claimmagic.com/cases/himshers-privacy-investigation . Shareholders may contact Berger Montague regarding the fiduciary duty investigation.